|
Title
|
Conference
|
Date
|
| From Insight to Foresight: Singapore’s Experience in Horizon Scanning of Medical Technologies |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Establishing the Implant Subsidy List in Singapore: A Collaborative Approach between Health Technology Assessment and National Procurement Agencies |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Singapore’s Experience with Implementing and Monitoring Risk-Sharing Arrangements for Drugs in the Public Healthcare Sector |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Charting a Sustainable Way to Subsidize Implants in Singapore |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Impact of the Cancer Drug List on Top 30 Cancer Drug Prices in Singapore’s Public Healthcare Sector |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Real-world Effectiveness of Umeclidinium and Umeclidinium/vilanterol for Chronic Obstructive Pulmonary Disease (COPD): A Singapore Database Study |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Company-led Submission For Cancer Medicines: The Singapore Experience |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Scanning the Right Horizons: Does Singapore’s Horizon Scanning Identify and Assess the Relevant Technologies? |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Impact of a Consumer Panel to Inform Health Technology Assessments and Policy Development: The Singapore Experience |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Does Patient Input Add Value to Healthcare Decision-Making? A 2-Year Reflection on Patient Involvement Processes in Singapore |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| A New Process for Patients and Caregivers to Suggest Health Technologies for Funding Consideration in Singapore |
Health Technology Assessment International (HTAi) 2024 Annual Meeting in Seville, Spain |
June 2024 |
| Helping patients become equal stakeholders in healthcare decision-making: The challenges and successes of patient involvement in Singapore |
1st International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Student Network Asia-Pacific Region Conference (ISPAC) (Virtual) |
February 2024 |
Characteristics of Patients with Symptomatic Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Implantation (TAVI): A Real-World Study in Singapore
|
The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2023 in Copenhagen, Denmark |
November 2023 |
| Cost-Effectiveness Analysis of Molnupiravir Against Standard Care for Treating Mild to Moderate COVID-19 Infection in Singapore |
The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2023 in Copenhagen, Denmark |
November 2023 |
| Cost-Effectiveness of Inclisiran as Add-on Therapy to Standard-of-Care for the Secondary Prevention of Cardiovascular Events in Patients with Elevated LDL Cholesterol |
The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2023 in Copenhagen, Denmark |
November 2023 |
| Real-world utilisation and outcomes of transcatheter mitral valve leaflet repair (TMVLR) in Asian patients with mitral regurgitation: A Singapore experience |
The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2023 in Copenhagen, Denmark |
November 2023 |
| The association of ESMO-Magnitude of Clinical Benefit Scale scores and subsidy decisions of targeted therapies for solid tumours in Singapore |
The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2023 in Copenhagen, Denmark
|
November 2023 |
| Patient Involvement in Drug Evaluations to Inform Funding Decisions: A Singapore Case Study |
Health Technology Assessment International (HTAi) 2023 Annual Meeting in Adelaide, Australia
|
June 2023 |
| Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Chemotherapy for Previously Treated HER2-Positive Gastric Cancer in Singapore |
Health Technology Assessment International (HTAi) 2023 Annual Meeting in Adelaide, Australia |
June 2023 |
| Increasing Emergence of Novel Digital Health Technologies Identified Through Horizon Scanning |
Health Technology Assessment International (HTAi) 2023 Annual Meeting in Adelaide, Australia |
June 2023 |
| Early Health Technology Assessment (HTA) of Medical Technologies to Inform Subsidy Decision-making in Singapore |
Health Technology Assessment International (HTAi) 2023 Annual Meeting in Adelaide, Australia |
June 2023 |
| Are We Ready for It? Developing Criteria to Include Artificial Intelligence Medical Devices (AI-MDs) For Health Technology Assessment (HTA) |
Health Technology Assessment International (HTAi) 2023 Annual Meeting in Adelaide, Australia |
June 2023 |
| Measuring the impact of subsidy decision on bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in Singapore |
9th HTAsiaLink Annual Virtual Conference 2021 |
October 2021 |
| Real-world data for measuring the impact of health technology assessment of drugs in Singapore |
9th HTAsiaLink Annual Virtual Conference 2021 |
October 2021 |
| Effect of drug subsidy policy on empagliflozin utilisation in Singapore: An interrupted time series analysis |
13th Asian Conference on Pharmacoepidemiology in Seoul, Korea (Virtual) |
October 2021 |
| Changes in prescribing practice of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in Singapore |
36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) (Virtual) |
September 2020 |
| Funding of treatments for rare diseases in Singapore |
17th HTA International Annual Meeting, Beijing, China (Virtual) |
June 2020 |
| Meta-Analysis of omalizumab and ciclosporin for chronic spontaneous urticaria |
16th HTA International Annual Meeting in Cologne, Germany |
June 2019 |
| Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) in chronic obstructive pulmonary disease: A systematic review and network meta-analysis |
8th ISPOR Asia Pacific in Tokyo, Japan |
September 2018 |
| Fluorodeoxyglucose positron emission tomography with computerised tomography for oncological indications: a pragmatic approach to guide subsidy decisions |
8th ISPOR Asia Pacific in Tokyo, Japan |
September 2018 |
| Cost-effectiveness analysis of sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore |
8th ISPOR Asia Pacific in Tokyo, Japan |
September 2018 |
| A pilot trial of value-based pricing for medical devices |
15th HTA International Annual Meeting in Vancouver, Canada |
June 2018 |
| Selection of non-drug medical technologies for evaluation in Singapore |
15th HTA International Annual Meeting in Vancouver, Canada |
June 2018 |
| Evolution of national drug evaluation processes in Singapore |
15th HTA International Annual Meeting in Vancouver, Canada |
June 2018 |